Chronic thromboembolic pulmonary hypertension (CTEPH) is a late sequel of venous thromboembolism that cannot be completely reproduced in animal models. The prevalence of CTEPH in humans is estimated at roughly 17-20 per million; however, partly because up to 50% of patients with CTEPH never experience symptomatic pulmonary embolism, precise numbers on the incidence and prevalence are not known....

The present article reports three clinical cases in order to elucidate the diversity of the pathophysiological mechanisms that underlie rheumatoid arthritis associated pulmonary hypertension. The condition's three major causes are: interstitial lung disease, vasculitis, and chronic thromboembolic disease, but it should be noted that the multiple pulmonary manifestations of rheumatoid arthritis,...

PURPOSE OF REVIEW Chronic thromboembolic pulmonary hypertension (CTEPH) is an important cause of pulmonary hypertension. Although surgery is potentially curative, some patients present with inoperable disease. In these patients, medical therapies for pulmonary arterial hypertension are increasingly being used. RECENT FINDINGS The pathobiology of CTEPH development remains incompletely understo...

Chronic thromboembolic pulmonary hypertension (CTPEH) is one of the few forms of pulmonary hypertension for which we have a clear and undisputed solution, i.e. pulmonary endarterectomy (PEA). In the vast majority of patients, PEA markedly improves or even cures the disease [1]. Over the years, surgeons have continuously improved their skills and are now reaching beyond the level of the subsegme...

The reasons for non-resolving thrombosis in chronic thromboembolic pulmonary hypertension (CTEPH) have not been fully elucidated. Despite platelets being implied in its pathogenesis, they have been poorly studied. We hypothesized that platelets would be altered in CTEPH. The aim of our study was to compare selected platelet parameters in CTEPH patients with healthy subjects. The study included ...

Chronic thromboembolic pulmonary hypertension (CTEPH) results from incomplete resolution of acute pulmonary emboli, organised into fibrotic material that obstructs large pulmonary arteries, and distal small-vessel arteriopathy. Pulmonary endarterectomy (PEA) is the treatment of choice for eligible patients with CTEPH; in expert centres, PEA has low in-hospital mortality rates and excellent long...

Chronic thromboembolic pulmonary hypertension (CTEPH) is a form of pulmonary hypertension caused by obstruction and vascular remodelling of pulmonary arteries following pulmonary embolism. Risk factors that predispose patients to CTEPH include the size of the initial thrombus and numerous associated host or medical conditions. Haemostatic risk factors include elevated levels of factor VIII and ...

Chronic thromboembolic pulmonary hypertension (CTEPH) is the only potentially curable form of pulmonary hypertension. Rapid and accurate diagnosis is pivotal for successful treatment. Clinical signs and symptoms can be nonspecific and risk factors such as history of venous thromboembolism may not always be present. Echocardiography is the recommended first diagnostic step. Cardiopulmonary exerc...

conclusions although we found a trend towards decreasing spah and improving 6mwd, no statistically significant shift were detected in our outcomes due to inadequate sample size. patients and methods a registered (irct201108257411n1), triple-blind, randomized controlled trial was performed in rasoule akram hospital, tehran, from 2009 to 2011. forty five patients with secondary pulmonary hyperten...

Chronic thromboembolic pulmonary hypertension (CTEPH) is responsible for significant levels of morbidity and mortality. The estimated cumulative incidence of CTEPH is 2-4% among patients presenting with acute pulmonary thromboembolism. Currently, at the time of CTEPH diagnosis, 37.9% of the patients in an international registry were receiving at least one pulmonary arterial hypertension (PAH)-t...